The clinical significance and mechanism of TLR4 polymorphisms in acute kidney injury induced by methotrexate

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100051011

Enrollment

Unknown

Registered

2021-09-10

Start date

2021-09-06

Completion date

Unknown

Last updated

2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary central nervous system lymphoma

Interventions

case series:none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. All patients underwent brain biopsy and were pathologically confirmed as diffuse large B-cell lymphoma (2016 WHO classification of lymphoid tumors), excluding other systemic involvement, and clinically diagnosed as PCNSL; 2. ECOG score 7.

Exclusion criteria

Exclusion criteria: 1. Patients allergic to MTX. Use of drugs that affect the evaluation of MTX-related adverse reactions, such as aminoglycoside antibiotics, non-steroidal anti-inflammatory drugs, and vancomycin, before or during the study; 2. The patient has any history of renal disease or renal dysfunction (eGFR<60ml/min/1.73m2); the patient has a history of HIV infection; 3. The patient suffers from serious medical diseases.

Design outcomes

Primary

Measure	Time frame
creatinine;TLR4 genotype;	—

Countries

China

Contacts

Public ContactWu Zhuo

Huashan Hospital, Fudan University

22371737@qq.com+86 21 52888380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026